Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8227091 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 9 Pages |
Abstract
Preoperative chemoRT with capecitabine plus oxaliplatin for distal rectal cancer has significant clinical activity (10 of 48 pCRs) and acceptable toxicity. This regimen is currently being evaluated in a Phase III randomized trial (National Surgical Adjuvant Breast and Bowel Project R04).
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Stuart J. M.D., Kathryn M.S., Neal J. M.D., Pramila Rani M.D., Lisa M.D., Asif M.D., James C. M.D., Edith M.D., Jondavid M.D., Robert Jeffrey M.D., Michael M.D., Beth A. M.D., Christopher G. M.D.,